http://www.mmm-online.com/hepatitis/topic/21798/ Articles tagged with Hepatitis from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon. http://www.mmm-online.com/jjs-janssen-looks-to-the-margins-with-hep-c-agent/article/293322/ Tue, 14 May 2013 17:10:47 GMT J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon. MMM Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise. http://www.mmm-online.com/merck-throws-more-staff-behind-januvia-overall-sales-slid-for-quarter/article/291560/ Wed, 01 May 2013 17:33:58 GMT Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise. MMM Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much. http://www.mmm-online.com/abbvie-reports-first-ever-quarter-downplays-pfizer-impact/article/290774/ Fri, 26 Apr 2013 17:11:16 GMT Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much. MMM The regulatory coup means BMS gets to work with FDA to develop its home-grown hep. C cocktail, which is on a competitive track to another hep. C alliance with Merck. http://www.mmm-online.com/bms-scores-breakthrough-label-for-hep-c-candidate/article/290573/ Thu, 25 Apr 2013 18:29:08 GMT The regulatory coup means BMS gets to work with FDA to develop its home-grown hep. C cocktail, which is on a competitive track to another hep. C alliance with Merck. MMM Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective. http://www.mmm-online.com/data-show-gileads-sofosbuvir-has-clean-safety-profile/article/290298/ Wed, 24 Apr 2013 14:56:10 GMT Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective. MMM GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment. http://www.mmm-online.com/business-briefs-gsk-astellas-vertex-and-orexigen/article/289879/ Mon, 22 Apr 2013 16:19:10 GMT GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment. MMM Roche and Isis pair up for Huntingtons, Vital's prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi's emerging market exposure grabs attention. http://www.mmm-online.com/business-briefs-roche-vital-art-and-science-gilead-sanofi/article/288107/ Tue, 09 Apr 2013 17:08:25 GMT Roche and Isis pair up for Huntingtons, Vital's prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi's emerging market exposure grabs attention. MMM BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year. http://www.mmm-online.com/business-briefs-bms-sanofi-uk-sunshine/article/287902/ Mon, 08 Apr 2013 16:57:33 GMT BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year. MMM Gilead combo drug clears HCV; FDA denies Xarelto expanded indication for a second time http://www.mmm-online.com/business-briefs-gilead-xarelto/article/283028/ Tue, 05 Mar 2013 16:41:18 GMT Gilead combo drug clears HCV; FDA denies Xarelto expanded indication for a second time MMM Teva kicks off a succession plan early, and Merck launches Phase II trials of two all-oral hepatitis C regimens. http://www.mmm-online.com/company-news-teva-merck-and-bms/article/267207/ Tue, 06 Nov 2012 19:09:38 GMT Teva kicks off a succession plan early, and Merck launches Phase II trials of two all-oral hepatitis C regimens. MMM